COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ

British Journal of Cancer

Volumn 90, Issue 2, 2004, Pages 423-429

  Boland, G P ^a   Butt, I S ^a   Prasad, R ^a   Knox, W F ^a   Bundred, N J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Breast COX 2; DCIS; HER 2; Oestrogen; Proliferation

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST DUCT; BREAST RECONSTRUCTION; CANCER GRADING; CANCER LOCALIZATION; CARCINOMA IN SITU; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL DIVISION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHENOTYPE; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 1342301548     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601534     Document Type: Article

References (54)

1. Allred DC, O'Connell P, Fuqua SA (1993) Biomarkers in early breast neoplasia. J Cell Biochem 17G(Suppl): 125-131
2. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000) Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 7: 1377-1381
3. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R (2001) Evaluation of the United States Food and Drug Administration - approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7: 1669-1675
4. Bobrow LG, Happerfield LC, Gregory WM, Millis RR (1995) Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 176: 333-341
5. Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ (2003a) Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 90: 426-432
6. Boland GP, Mckeown A, Chan KC, Prasad R, Knox WF, Bundred NJ (2003b) Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast. Br J Cancer 89: 227-283
7. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E (2001) Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121: 1339-1347
8. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55: 429-434
9. Davies G, Martin LA, Sacks N, Dowsett M (2002) Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13: 669-678
10. Denkert C, Winzer K-J, Muller B-M, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease survival and overall survival in patients with breast cancer. Cancer 97: 2978-2987
11. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME, Scott T, Muchmore DB (2001) Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 10: 961-966
12. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188
13. Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ (1998) Evidence of significant apoptosis in poorly differentiated ductal carcinoma in situ of the breast Br J Cancer 78: 788-794
14. Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ (2000) Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ. Cancer Res 60: 4284-4288
15. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681
16. Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101-2103
17. Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS (2002) Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 94: 1023-1031
18. Holland PA, Knox WF, Potten CS, Howell A, Anderson E, Baildam AD, Bundred NJ (1997) Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J Natl Cancer Inst 89: 1059-1065
19. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ (2002) Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62: 5405-5407
20. Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455-460
21. Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84: 1188-1192
22. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, Levine AC (2000) Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56: 671-676
23. Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, Koch MO, Shappell SB, Breyer MD (2000) Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157: 29-35
24. Kundu N, Fulton AM (2002) Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62: 2343-2346
25. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569
26. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120: 1713-1719
27. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT (1999) Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59: 5647-5650
28. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia- adenocarcinoma sequence. Am J Gastroenterol 96: 990-996
29. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G (2002) Transgenic cylclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 99: 12483-12488
30. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM (1997) Cyclooxygenase-2 expression in human breast cancer. Int J Oncol 10: 503-507
31. Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C (2001) Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158: 849-853
32. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635
33. Rozic JG, Chakraborty C, Lala PK (2001) Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93: 497-506
34. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP, Jabbour HN (2001) Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endacrinol Metab 86: 2243-2249
35. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789
36. Shaheen NJ, Straus WL, Sandler RS (2002) Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer 94: 950-963
37. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H, Monden M (2000) Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 6: 1229-1238
38. Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman LJ (2003) Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 63: 2347-2350
39. Shirahama T (2000) Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6: 2424-2430
40. Shirahama T, Arima J, Akiba S, Sakakura C (2001) Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92: 188-193
41. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, Poller DN (1996) A prognostic index for ductal carcinoma in situ of the breast. Cancer 77: 2267-2274
42. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645
43. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R, Obrist P (2003) Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88: 574-578
44. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002a) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277: 18649-18657
45. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002b) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277: 18649-18657
46. Suo Z, Bjaamer A, Ottestad L, Nesland JM (2001) Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast. Ultrastruct Pathol 25: 349-356
47. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501
48. Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340
49. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716
50. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S (2002) Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 79: 216-223
51. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey III TJ (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59: 987-990
52. Vadlamudi R, Mandai M, Adam L, Steinbach G, Mendelsohn J, Kumar R (1999) Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18: 305-314
53. Watanabe O, Shimizu T, Kinoshita J, Utada Y, Okabe T, Kimura K, Hirano A, Yoshimatsu K, Aiba M, Ogawa K (2003) Expression of cyclooxygenase-2 in malignant and benign breast tumours. Anticancer Res 23: 3215-3221
54. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A (1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001